Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Equity Average: 2016-2025

Historic Equity Average for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $244.2 million.

  • Organogenesis Holdings' Equity Average fell 9.90% to $244.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $244.2 million, marking a year-over-year decrease of 9.90%. This contributed to the annual value of $270.8 million for FY2024, which is 0.51% down from last year.
  • Per Organogenesis Holdings' latest filing, its Equity Average stood at $244.2 million for Q3 2025, which was up 2.57% from $238.1 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Equity Average registered a high of $278.3 million during Q1 2024, and its lowest value of $149.6 million during Q1 2021.
  • Moreover, its 3-year median value for Equity Average was $270.7 million (2024), whereas its average is $264.5 million.
  • In the last 5 years, Organogenesis Holdings' Equity Average soared by 342.13% in 2021 and then dropped by 12.07% in 2025.
  • Organogenesis Holdings' Equity Average (Quarterly) stood at $215.3 million in 2021, then grew by 21.25% to $261.0 million in 2022, then increased by 6.42% to $277.8 million in 2023, then dropped by 2.54% to $270.7 million in 2024, then declined by 9.90% to $244.2 million in 2025.
  • Its Equity Average stands at $244.2 million for Q3 2025, versus $238.1 million for Q2 2025 and $252.9 million for Q1 2025.